Organization · Venture Capital
Óskare Capital
Óskare Capital is a venture capital firm based in Paris and London, focusing on investments in the Deeptech and Life Sciences sectors, particularly in innovative companies targeting the endocannabinoid system.
Overview
What Óskare Capital does
What Óskare Capital is
Óskare Capital is a venture capital firm based in Paris and London, focusing on investments in the Deeptech and Life Sciences sectors, particularly in innovative companies targeting the endocannabinoid system.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 2020
- Approximate age
- About 6 years
- Structured capabilities
- Funder
- Last reviewed
- April 24, 2026
Official channels
Find Óskare Capital elsewhere
Open the official website or a supported primary organization account.
Capability profile
Óskare Capital as a funder
Investment thesis
Óskare Capital specializes in medical cannabinoid and endocannabinoid system therapeutics, backing innovative European companies in Deeptech and Life Sciences.
Focus narrative
Óskare Capital invests in companies within the Deeptech and Life Sciences sectors, targeting venture-stage investments. The firm seeks to identify and support innovative solutions that have the potential to disrupt traditional markets and improve quality of life through advanced technologies.
Value beyond capital
Óskare Capital adds value to its portfolio companies through strategic guidance, access to a network of industry experts, and support in navigating the complexities of the Deeptech and Life Sciences sectors. The firm leverages its team's extensive experience and partnerships to help companies scale and succeed in their respective markets.
Terms and economics
- Typical check
- $500,000–$5,000,000
- Sweet spot
- $2,000,000
Focus and fit
- Stages
- Pre-seed · Seed · Series A
- Regions
- EuropeNorth America
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 5
Portfolio context
Octarine Bio: A Danish company developing a synthetic biology platform for sustainable bio-based dyes. Invested at the Pre-Seed stage in 2019. Herbolea: An Italian and US-based company that transforms botanicals into high-quality products using proprietary, solvent-less technologies. Invested at the Seed stage in 2020. Leva: A UK-based digital clinic for chronic pain management, providing alternatives to opiates. Invested at the Seed stage in 2021. Prohibition Partners: A UK company known for hosting European conferences and providing data in the cannabis sector. Invested at the Series A stage in 2022. Aelis Farma: A French clinical biopharmaceutical company focused on brain disease treatments, including addiction and Down’s Syndrome. Invested at the Post-IPO stage in 2022.
Common questions
What to know about Óskare Capital
Upseed classifies Óskare Capital under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
April 24, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.